Galectin Therapeutics Incis A Clinical Stage Biopharmaceutical Company Based In Norcrossgeorgiathe Company Focuses On Developing Innovative Therapies For Chronic Liver Diseases And Cancerparticularly Targeting Conditions Like Non Alcoholic Steatohepatitisnashcirrhosis And Fibrosisby Leveraging Its Expertise In Galectin Sciencegalectin Therapeutics Aims To Improve Patient Outcomes And Reduce The Need For Liver Transplants One Of The Key Products In Their Pipeline Is Belapectingr Md 02 A Carbohydrate Based Drug That Inhibits The Galectin 3 Proteinthis Drug Is Currently Undergoing A Phase 2B 3 Clinical Trial For Patients With Portal Hypertension And Esophageal Varices Riskadditionallybelapectin Is Being Studied In Combination With Checkpoint Inhibitors For Advanced Melanoma And Other Cancersthe Company Collaborates With Academic Institutions To Explore Further Applications Of Galectin 3 Related Therapiesenhancing Its Research Capabilities
